Literature DB >> 7597381

Anticentromere antibody--clinical associations. A study of 44 patients.

P Caramaschi1, D Biasi, T Manzo, A Carletto, F Poli, L M Bambara.   

Abstract

The objective of this study was to determine the clinical features of 44 patients with anticentromere antibody (ACA) positivity. We undertook a retrospective review of 44 ACA-positive patients (1 male and 43 females with a mean +/- SD age of 53.6 +/- 12.2 years). There were 25 patients with limited systemic sclerosis, 12 with Raynaud's disease, 2 with Sjögren's syndrome, 2 with systemic lupus erythematosus and 3 with polyarthritis. ACA was more frequently found in patients affected by limited systemic sclerosis with mild visceral involvement and in patients with Raynaud's disease. Moreover, ACA was detected in other connective tissue diseases that were characterized by an atypical autoantibody profile.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7597381     DOI： 10.1007/BF00262092

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  14 in total

1.  Letter: Technique for parotid biopsy.

Authors:  H A Kraaijenhagen
Journal:  J Oral Surg       Date:  1975-05

2.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

3.  Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis.

Authors:  F M Wigley; R A Wise; R Miller; B W Needleman; R J Spence
Journal:  Arthritis Rheum       Date:  1992-06

4.  Anticentromere antibodies--clinical correlates.

Authors:  J P Wade; B Sack; P H Schur
Journal:  J Rheumatol       Date:  1988-12       Impact factor: 4.666

5.  Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients.

Authors:  E S Weiner; W C Earnshaw; J L Senécal; B Bordwell; P Johnson; N F Rothfield
Journal:  Arthritis Rheum       Date:  1988-03

6.  Anticentromere antibody in primary biliary cirrhosis.

Authors:  R M Bernstein; M E Callender; J M Neuberger; G R Hughes; R Williams
Journal:  Ann Rheum Dis       Date:  1982-12       Impact factor: 19.103

7.  Patients with anticentromere antibodies, clinical features, diagnoses and evolution.

Authors:  P G Vlachoyiannopoulos; A A Drosos; A Wiik; H M Moutsopoulos
Journal:  Br J Rheumatol       Date:  1993-04

8.  Cutaneous and serologic subsets of systemic sclerosis.

Authors:  C Ferri; L Bernini; R Cecchetti; A Latorraca; G Marotta; G Pasero; R Neri; S Bombardieri
Journal:  J Rheumatol       Date:  1991-12       Impact factor: 4.666

9.  The CREST syndrome: a distinct serologic entity with anticentromere antibodies.

Authors:  M J Fritzler; T D Kinsella
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

10.  D-penicillamine (DPA)-induced anticentromere antibody (ACA)

Authors:  G Haberhauer
Journal:  Clin Exp Rheumatol       Date:  1989 May-Jun       Impact factor: 4.473
View more
  12 in total

1.  Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis.

Authors:  C Rigamonti; L M Shand; M Feudjo; C C Bunn; C M Black; C P Denton; A K Burroughs
Journal:  Gut       Date:  2005-09-08       Impact factor: 23.059

2.  The value of pattern capillary changes and antibodies to predict the development of systemic sclerosis in patients with primary Raynaud's phenomenon.

Authors:  Slavica R Pavlov-Dolijanovic; Nemanja S Damjanov; Nada Z Vujasinovic Stupar; Snezana Baltic; Dragan D Babic
Journal:  Rheumatol Int       Date:  2013-08-11       Impact factor: 2.631

3.  Finger skin temperature in patients affected by Raynaud's phenomenon with or without anticentromere antibody positivity.

Authors:  P Caramaschi; D Biasi; A Carletto; T Manzo; M Randon; S Zeminian; L M Bambara
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

4.  Fine specificity mapping of autoantigens targeted by anti-centromere autoantibodies.

Authors:  Yasmin Akbarali; Jennifer Matousek-Ronck; Laura Hunt; Leslie Staudt; Morris Reichlin; Joel M Guthridge; Judith A James
Journal:  J Autoimmun       Date:  2007-01-08       Impact factor: 7.094

5.  Incidence and clinical correlation of anticentromere antibody in Thai patients.

Authors:  Krisaree Pakunpanya; Oravan Verasertniyom; Monchand Vanichapuntu; Prapaporn Pisitkun; Kitti Totemchokchyakarn; Kanokrat Nantiruj; Suchela Janwityanujit
Journal:  Clin Rheumatol       Date:  2005-10-12       Impact factor: 2.980

Review 6.  Anti-nuclear autoantibodies in systemic sclerosis : News and perspectives.

Authors:  Yasuhito Hamaguchi; Kazuhiko Takehara
Journal:  J Scleroderma Relat Disord       Date:  2018-07-10

7.  Anticentromere antibody positive Sjögren's Syndrome: a retrospective descriptive analysis.

Authors:  Vasiliki-Kalliopi K Bournia; Konstantina D Diamanti; Panayiotis G Vlachoyiannopoulos; Haralampos M Moutsopoulos
Journal:  Arthritis Res Ther       Date:  2010-03-13       Impact factor: 5.156

8.  Anti-centromere antibody-seropositive Sjögren's syndrome differs from conventional subgroup in clinical and pathological study.

Authors:  Hideki Nakamura; Atsushi Kawakami; Tomayoshi Hayashi; Naoki Iwamoto; Akitomo Okada; Mami Tamai; Satoshi Yamasaki; Hiroaki Ida; Katsumi Eguchi
Journal:  BMC Musculoskelet Disord       Date:  2010-07-01       Impact factor: 2.362

9.  Clinical characteristics of patients with hepatitis C virus-related chronic liver disease seropositive for anticentromere antibody.

Authors:  Takashi Himoto; Seiji Nakai; Fumihiko Kinekawa; Hirohito Yoneyama; Akihiro Deguchi; Kazutaka Kurokochi; Tsutomu Masaki; Shoichi Senda; Reiji Haba; Seishiro Watanabe; Mikio Nishioka; Shigeki Kuriyama
Journal:  Dig Dis Sci       Date:  2008-07-16       Impact factor: 3.199

10.  Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome.

Authors:  R Wu; O Shovman; Y Zhang; B Gilburd; G Zandman-Goddard; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2007-02       Impact factor: 10.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.